BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (BBIO) has granted equity awards to 36 new employees in the form of restricted stock units totaling 101,974 shares of common stock. The grants were approved by the compensation committee on May 9, 2025. The vesting schedule includes 25% of shares vesting on May 16, 2026, followed by quarterly vesting of the remaining shares in one-twelfth increments, contingent on continued employment. These inducement grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma (BBIO) ha assegnato premi azionari a 36 nuovi dipendenti sotto forma di unità azionarie vincolate per un totale di 101.974 azioni ordinarie. Le assegnazioni sono state approvate dal comitato per la remunerazione il 9 maggio 2025. Il piano di maturazione prevede che il 25% delle azioni maturi il 16 maggio 2026, seguito da una maturazione trimestrale delle azioni rimanenti in incrementi di un dodicesimo, subordinata alla continuazione del rapporto di lavoro. Questi premi di incentivo sono stati concessi ai sensi del Piano di Incentivazione Azionaria Modificato e Ristabilito del 2019 di BridgeBio, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
BridgeBio Pharma (BBIO) ha otorgado premios de acciones a 36 nuevos empleados en forma de unidades de acciones restringidas que suman un total de 101,974 acciones ordinarias. Las concesiones fueron aprobadas por el comité de compensación el 9 de mayo de 2025. El calendario de adquisición incluye que el 25% de las acciones se liberen el 16 de mayo de 2026, seguido de una adquisición trimestral de las acciones restantes en incrementos de un doceavo, condicionado a la continuidad del empleo. Estas concesiones por inducción se realizaron bajo el Plan de Acciones por Incentivos Modificado y Reestablecido de BridgeBio de 2019, de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
BridgeBio Pharma (BBIO)는 36명의 신규 직원에게 총 101,974주의 보통주 제한 주식 단위 형태로 주식 보상을 부여했습니다. 이 보상은 2025년 5월 9일 보상 위원회에서 승인되었습니다. 베스팅 일정은 2026년 5월 16일에 25%의 주식이 베스팅되고, 이후 나머지 주식은 1/12씩 분기별로 베스팅되며, 계속 고용 조건이 충족되어야 합니다. 이 유인 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 BridgeBio의 2019년 개정 및 재확인된 유인 주식 계획에 따라 이루어졌습니다.
BridgeBio Pharma (BBIO) a accordé des attributions d'actions à 36 nouveaux employés sous forme d'unités d'actions restreintes totalisant 101 974 actions ordinaires. Ces attributions ont été approuvées par le comité de rémunération le 9 mai 2025. Le calendrier d'acquisition prévoit que 25 % des actions seront acquises le 16 mai 2026, suivies d'une acquisition trimestrielle des actions restantes par incréments d'un douzième, sous réserve de la poursuite de l'emploi. Ces attributions d'incitation ont été effectuées dans le cadre du Plan d'Attribution d'Actions d'Incitation modifié et restitué de BridgeBio de 2019, conformément à la règle de cotation Nasdaq 5635(c)(4).
BridgeBio Pharma (BBIO) hat 36 neuen Mitarbeitern Aktienzuteilungen in Form von Restricted Stock Units in Höhe von insgesamt 101.974 Stammaktien gewährt. Die Zuteilungen wurden am 9. Mai 2025 vom Vergütungsausschuss genehmigt. Der Vesting-Zeitplan sieht vor, dass 25 % der Aktien am 16. Mai 2026 freigegeben werden, gefolgt von vierteljährlicher Freigabe der verbleibenden Aktien in Zwölftel-Schritten, abhängig von fortgesetztem Arbeitsverhältnis. Diese Anreizzuteilungen erfolgten im Rahmen des geänderten und neu gefassten Inducement Equity Plans von BridgeBio aus dem Jahr 2019, gemäß der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube.
BridgeBio Media Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, VP IR & Strategic Finance
Chinmay.shukla@bridgebio.com
FAQ
How many shares were granted in BridgeBio's (BBIO) May 2025 inducement grants?
What is the vesting schedule for BBIO's May 2025 restricted stock unit grants?
Under which plan were BridgeBio's May 2025 inducement grants made?
Why did BridgeBio (BBIO) issue these equity grants in May 2025?
